Banner - NPPA Connect
Logo Image
Opinion|Videos|March 21, 2025

Mechanism of Action Differences Among IL-17 Inhibitors

Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.

Episodes in this series

Video content above is prompted by the following:

  • How do the mechanisms of action of the approved IL-17 inhibitors differ from one another, and how might these differences translate in terms of efficacy and/or safety?
    • Secukinumab (IL-17A inhibitor)—approved 2015
    • Ixekizumab (IL-17A inhibitor)—approved 2016
    • Brodalumab (IL-17RA inhibitor)—approved 2017
    • Bimekizumab (IL-17A and IL-17F inhibitor)—approved 2023

Related Content

Latest CME

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management
Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

View more
Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches
Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

View more
Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes
Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

View more